The global HIV/AIDS vaccine enterprise: Scientific strategic plan

被引：36

作者：

Bhan, MK

Berkley, S

DeWilde, M

Esparza, J ^{[1
]}

Fauci, AS

Gayle, H

Johnston, MI

Kaleebu, P

Kazatch-Kine, MD

Klausner, RD

Lander, ES

Makgoba, MW

Mocumbi, P

Piot, P

Quintana-Trias, O

Snow, W

Walport, MJ

Wigzell, H

机构：

[1] Bill & Melinda Gates Fdn, Seattle, WA USA

[2] Dept Biotechnol, New Delhi, India

[3] Int AIDS Vaccine Initiat, New York, NY USA

[4] Aventis Pasteur, Swiftwater, PA USA

[5] NIH, Bethesda, MD 20892 USA

[6] Uganda Virus Res Inst, Entebbe, Uganda

[7] Agence Natl Rech SIDA, Paris, France

[8] MIT, Cambridge, MA USA

[9] Univ KwaZulu Natal, Durban, South Africa

[10] European & Dev Countries Clin Trials Partnership, The Hague, Netherlands

[11] UN Programme HIV AIDS, Geneva, Switzerland

[12] Commiss European Communities, B-1049 Brussels, Belgium

[13] AIDS Vaccines Advocacy Coalit, New York, NY USA

[14] Wellcome Trust Res Labs, London, England

[15] Karolinska Inst, Stockholm, Sweden

来源：

PLOS MEDICINE | 2005年 / 2卷 / 02期

关键词：

D O I：

10.1371/journal.pmed.0020025

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：111 / 121

页数：11

共 28 条

[1] Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection [J].

Allen, TM ;

Altfeld, M ;

Yu, XG ;

O'Sullivan, KM ;

Lichterfeld, M ;

Le Gall, S ;

John, M ;

Mothe, BR ;

Lee, PK ;

Kalife, ET ;

Cohen, DE ;

Freedberg, KA ;

Strick, DA ;

Johnston, MN ;

Sette, A ;

Rosenberg, ES ;

Mallal, SA ;

Goulder, PJR ;

Brander, C ;

Walker, BD .

JOURNAL OF VIROLOGY, 2004, 78 (13) :7069-7078

[2] HIV escape from cytotoxic T lymphocytes: a potential hurdle for vaccines? [J].

Barouch, DH ;

Letvin, NL .

LANCET, 2004, 364 (9428) :10-11

[3] Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity [J].

Barouch, DH ;

Pau, MG ;

Custers, JHHV ;

Koudstaal, W ;

Kostense, S ;

Havenga, MJE ;

Truitt, DM ;

Sumida, SM ;

Kishko, MG ;

Arthur, JC ;

Korioth-Schmitz, B ;

Newberg, MH ;

Gorgone, DA ;

Lifton, MA ;

Panicali, DL ;

Nabel, GJ ;

Letvin, NL ;

Goudsmit, J .

JOURNAL OF IMMUNOLOGY, 2004, 172 (10) :6290-6297

[4]

BING A, 2004, 15 INT AIDS C 2004 J

[5] HIV vaccine design and the neutralizing antibody problem [J].

Burton, DR ;

Desrosiers, RC ;

Doms, RW ;

Koff, WC ;

Kwong, PD ;

Moore, JP ;

Nabel, GJ ;

Sodroski, J ;

Wilson, IA ;

Wyatt, RT .

NATURE IMMUNOLOGY, 2004, 5 (03) :233-236

[6] Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission [J].

Derdeyn, CA ;

Decker, JM ;

Bibollet-Ruche, F ;

Mokili, JL ;

Muldoon, M ;

Denham, SA ;

Heil, ML ;

Kasolo, F ;

Musonda, R ;

Hahn, BH ;

Shaw, GM ;

Korber, BT ;

Allen, S ;

Hunter, E .

SCIENCE, 2004, 303 (5666) :2019-2022

[7] Prospects for an AIDS vaccine [J].

Desrosiers, RC .

NATURE MEDICINE, 2004, 10 (03) :221-223

[8] HIV and AIDS: 20 years of science [J].

Fauci, AS .

NATURE MEDICINE, 2003, 9 (07) :839-843

[9] Clinical trials of HIV vaccines [J].

Graham, BS .

ANNUAL REVIEW OF MEDICINE, 2002, 53 :207-221

[10] Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda [J].

Gray, RH ;

Wawer, MJ ;

Brookmeyer, R ;

Sewankambo, NK ;

Serwadda, D ;

Wabwire-Mangen, F ;

Lutalo, T ;

Li, XB ;

vanCott, T ;

Quinn, TC .

LANCET, 2001, 357 (9263) :1149-1153

← 1 2 3 →